Drug Approval | May 24, 2022
Cadila Pharma launches Belmore to treat uncontrolled LDL-cholesterol
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
The findings support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Subscribe To Our Newsletter & Stay Updated
